Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $16.02, for a total value of $160,200.00. Following the sale, the insider now directly owns 1,174,662 shares in […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $16.02, for a total value of $160,200.00. Following the completion of the sale, the insider now owns 1,174,662 […]
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 12 2% on Analyst Upgrade theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most.
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 12 2% on Analyst Upgrade themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.